# Incyte Corporation > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Incyte Corporation). ## Overview Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines. Its business is concentrated in hematology, oncology, and inflammation/autoimmunity, with revenue driven by marketed drugs such as JAKAFI, OPZELURA, MONJUVI/MINJUVI, and NIKTIMVO plus royalties and collaboration income. ## Products & services • JAKAFI (ruxolitinib) for myelofibrosis, polycythemia vera, and GVHD • OPZELURA (ruxolitinib cream) for atopic dermatitis and vitiligo • MONJUVI/MINJUVI (tafasitamab) for hematologic cancers • NIKTIMVO (axatilimab-csfr) for chronic GVHD • Royalties from partnered products such as JAKAVI/JAKAVI-like rights • Clinical development and licensing collaborations in oncology and immunology - **Commercial hematology products** (55%) — Approved medicines for myelofibrosis, polycythemia vera, GVHD, and related blood cancers. - **Dermatology / inflammation products** (25%) — Topical and systemic therapies for inflammatory skin and immune-mediated diseases. - **Royalty revenue** (10%) — Royalties earned from partnered products sold by collaborators in certain markets. - **Collaborations and licensing** (10%) — Upfront, milestone, and other collaboration-related revenue from partnered R&D programs. - JAKAFI (ruxolitinib) oral therapy for myelofibrosis, PV, and GVHD - OPZELURA topical ruxolitinib for atopic dermatitis and vitiligo - MONJUVI/MINJUVI tafasitamab for blood cancer indications - NIKTIMVO axatilimab for chronic GVHD - Royalty income from partnered products and territories - Clinical-stage pipeline and out-licensing collaborations ## Customers Incyte sells primarily to specialty and retail pharmacies, specialty distributors, wholesalers, hospital pharmacies, and an exclusive wholesaler outside the U.S. The end users are patients treated by hematologists, oncologists, dermatologists, transplant specialists, and other physicians managing rare cancers and immune-mediated diseases. - **Specialty pharmacies and distributors** (primary) — Buy and dispense Incyte's branded medicines, especially chronic therapies like JAKAFI and OPZELURA. - **Hospitals and transplant centers** (primary) — Purchase therapies used in GVHD and oncology settings where administration and reimbursement are hospital-linked. - **Physicians and clinical specialists** (primary) — Prescribe Incyte's medicines to patients with hematologic malignancies, GVHD, and inflammatory skin disease. - **Partner companies and licensees** (secondary) — Commercialize partnered assets in certain geographies and pay royalties or milestones to Incyte. - Specialty pharmacies dispensing chronic branded therapies - Wholesalers and specialty distributors stocking commercial products - Hospital pharmacies for transplant and oncology use cases - Physicians treating rare blood cancers and GVHD patients - Dermatology prescribers for atopic dermatitis and vitiligo - Partners/licensees that commercialize products in selected territories ## Geography Incyte is globally organized, with headquarters and commercial operations in Wilmington, Delaware, plus major regional hubs in Morges, Switzerland, Tokyo, and Montreal. The company reported that 70% of employees were based in the U.S. and Canada, 27% in Europe, and 3% in Asia, reflecting a business that is operationally global but still anchored in North America and Europe. - **United States and Canada** (70%) — Employee base concentration, not revenue. - **Europe** (27%) — Employee base concentration and commercial footprint. - **Asia** (3%) — Employee base concentration and Japanese headquarters. - U.S. is the core commercial and R&D base - Europe is a major commercial region via Morges and local offices - Japan and Canada support regional commercialization and development - Outside-U.S. product sales are meaningful for OPZELURA and other products - Global footprint matters for regulatory approvals and launch execution ## Strategy Incyte's strategy is to develop and commercialize internally discovered or in-licensed therapies in markets where it can compete effectively, while using partnerships to extend reach where it lacks scale or expertise. The company is also expanding its commercial infrastructure outside the U.S. to support recent launches and broaden the contribution from ex-U.S. markets. - **Expand commercial reach for approved products** (short-term) — More indications and more geographies increase the lifetime value of each asset. - **Advance the clinical pipeline in hematology, oncology, and IAI** (medium-term) — Pipeline success is needed to offset eventual patent expiry and sustain growth. - **Use collaborations to broaden reach and reduce development burden** (medium-term) — Partners can provide local expertise, funding, and commercialization scale. - Grow marketed products through new indications and geographic expansion - Use partnerships to accelerate development and commercialization - Build commercial capabilities in Europe, Japan, and Canada - Support launches of recently approved products like NIKTIMVO - Protect and extend value through patents and exclusivity ## Risks Incyte faces typical biopharma risks around clinical trial failure, regulatory approval, patent protection, and product liability, but also company-specific dependence on a small number of marketed products. Manufacturing complexity, especially for antibody-based products, and reliance on third-party contract manufacturers can disrupt supply and delay launches or approvals. - **Concentration in a limited set of commercial products** [high] — A large share of revenue comes from a small number of therapies, so any demand slowdown or competition can materially affect results. - **Clinical development and regulatory risk** [high] — Pipeline assets require successful trials and approvals, and failures can remove expected future revenue streams. - **Manufacturing and third-party supply risk** [high] — Antibody manufacturing is complex and depends on contract manufacturers and regulatory approvals for facilities. - **Patent and exclusivity erosion** [high] — Loss of patent protection or successful challenges can reduce pricing power and royalty value. - **Product liability and safety perception** [medium] — Adverse events or perceived safety issues can reduce prescribing and trigger claims or label restrictions. - Heavy dependence on a few branded products and indications - Clinical development failures can eliminate future growth drivers - Patent expiry or weak IP protection can reduce product value - Manufacturing and supply chain issues can disrupt launches and sales - Regulatory actions or safety concerns can limit approvals and prescribing ## Accounting Incyte's revenue is recognized at a point in time when control of product is transferred, but reported product revenue is reduced by estimates for returns, rebates, chargebacks, prompt-pay discounts, and co-pay assistance. Quarterly results can be volatile because customer inventory building, launch timing, and ex-U.S. uptake can shift revenue between periods, while collaboration and royalty streams add another layer of judgment. - **Revenue allowances and deductions** — Affects product revenue and gross-to-net trends - **Point-in-time product revenue recognition** — Can create quarter-to-quarter volatility - **Royalty and collaboration revenue recognition** — Affects non-product revenue mix - **Estimates for contingencies and product liability** — Can affect operating expenses and reserves - Net product revenue depends on estimates of rebates, returns, and chargebacks - Revenue is recognized at a point in time when control transfers - Quarterly sales can swing with inventory builds and launch timing - Royalty and collaboration revenue depend on partner sales and contract terms - Cash and marketable securities are invested in interest-bearing instruments --- *Last updated: 2026-08-11T04:03:56.228997+00:00*